Abemaciclib for the treatment of breast cancer.

@article{Kotake2018AbemaciclibFT,
  title={Abemaciclib for the treatment of breast cancer.},
  author={Takeshi Kotake and Masakazu Toi},
  journal={Expert opinion on pharmacotherapy},
  year={2018},
  volume={19 5},
  pages={517-524}
}
INTRODUCTION There have been numerous clinical trials of CDK4/6 inhibitors performed on various carcinomas including breast cancer. One such inhibitor tested and which has ongoing clinical trials for breast cancer is abemaciclib. Abemaciclib is a molecular-targeted agent that targets basic cell cycle regulatory mechanisms. Areas covered: This review discusses the available clinical data and ongoing clinical trials of abemaciclib in breast cancer. Expert opinion: Abemaciclib has demonstrated a… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 27 references

Abstract S4-06: biological effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+, HER2- breast cancer

  • S Hurvitz, M Martin, M Fernández Abad
  • Cancer Res
  • 2017

abstract] Abemaciclib for the treatment of brain metastases (BM) secondary to hormone receptor positive (HR+), HER2 negative breast cancer

  • SM Tolaney, NU Lin, D Thornton
  • ASCO Meeting Abstracts
  • 2017

A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer

  • M Beeram, SM Tolaney, JT Beck
  • Ann Oncol. 2016;27(suppl_6):LBA18– LBA18
  • 2016

Breast cancer, early stage interim results from neoMONARCH: A neoadjuvant phase II study of abemaciclib in postmenopausal women with HR +/HER2- breast cancer

  • S Hurvitz, MF Abad, R Rostorfer
  • (BC). Ann Oncol
  • 2016

Similar Papers

Loading similar papers…